• New bioproduction campaign under GMP conditions according to a new innovative and robust industrial process
• Subscription to an equity financing line for a maximum amount of 12 million euros with IRIS
Toulouse, FRANCE, Lakeland, UNITED STATES, May 23, 2023, 8:30 p.m. – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the sole Apoa- I human recombinant in the world, announces the acceleration of its development by launching a new bioproduction campaign using its new robust and innovative process, supported by the establishment of an equity financing line.
To receive information from ABIONYX Pharma in real time, send a request to [email protected].